האיגוד הישראלי לרפואת משפחה
כעת 6793 ערכים
רופאים, הרשמו עכשיו למועדון העורכים כניסה עקבו אחרינו בפייסבוק
האיגוד הישראלי לרפואת משפחה
רופאים, הרשמו עכשיו למועדון העורכים כניסה עקבו אחרינו בפייסבוק
כעת 6793 ערכים
האיגוד הישראלי לרפואת משפחה

המלצות כוח המשימה הישראלי בנושא קידום בריאות ורפואה מונעת/תוספת ביבליוגרפיה למהדורת 2004

מתוך ויקירפואה

המלצות כוח המשימה הישראלי בנושא
קידום בריאות ורפואה מונעת
Ambox warning blue.png
ערך זה הוא הנחיה קלינית סגורה לעריכה
המלצות כוח המשימה.png
שם הפרק תוספת ביבליוגרפיה למהדורת 2004
עורך מדעי פרופסור אמנון להד, פרופ' חוה טבנקין, ד"ר תם אקסלרוד
מוציא לאור ההסתדרות הרפואית בישראל, האגף למדיניות רפואית, איגוד רופאי המשפחה בישראל
מועד הוצאה אוקטובר 2022
מספר עמודים 284
קישור באתר ההסתדרות הרפואית
Logo small.gif

כללי

  • 209   U.S. Preventive Services Task Force Guide to Clinical Preventive Services, Third Edition: Periodic Updates. Vol. 1 - Methods and screening. Agency for health care research and quality, www.ahrq.gov, AHRQ Publication No 02-500 Sep 2002.
  • 210   U.S. preventive Services Task force Guide to Clinical preventive Services, Third Edition: Periodic Updates. Vol. 2 - Chemoprevention and counseling. HARQ, Publication No 02-500 Sep 2002.
  • 211   מגמות בתחלואה ובתמותה מסרטן בישראל. הוצאת האגודה למלחמה בסרטן והמרכז .211 הלאומי לבקרת מחלות, משרד הבריאות 1998.
  • 212   בריאות בישראל נתונים נבחרים. בעריכת אבורבה מ, עוזרי ר, גורדון ש, שטיין נ, מרציאנו א, חקלאי צ. משרד הבריאות מדינת ישראל 2001. ועדכון דו"ח הלשכה המרכזית לסטטיסטיקה לוחות 6.13,6.14.

ילדים ומתבגרים

  • 213    בריאות התלמיד מידע שימושי. בעריכת בארי קנישקווי, יונה אמיתי, מירה חונוביץ. משרד הבריאות, שירותי בריאות הציבור, המחלקה לאם, לילד ולמתבגר, הסיעוד בבריאות הציבור, המחלקה לחינוך לבריאות. הפקה שראל שמתים ואספקה רפואית בע"מ 2003.
  • 214   Weinstein SL, Lori A Dolan, Spratt KF. Health and function of patients with untreated idiopathic scoliosis. JAMA 2003; 289: 559-567.

אלימות במשפחה וכנגד נשים

  • 215    MacMiller HL, Wathen CN with the Canadian Task Force on Preventive Health Care. Prevention and treatment of violence against women - systematic review and recommenda¬tion. www.ctfphc.org/Tables/Domestic_Violence_tab.htm.
  • 216    Rhodes KV, Levinson W. Interventions for intimate partner violence against women. JAMA 2003; 289: 601-605.
  • 217    Wathen CN & MacMillan HL. Interventions for violence against women. JAMA 2003; 289: 589-600.
  • 218    Krug EG, Mercy JA, Dahlberg LL, Zwi AB. The world report on violence and health. Lancet 2002; 360: 1083-1088.
  • 219    אלימות בין בני זוג - עמדת ההסתדרות הרפואית בישראל והנחיות לרופאים בדבר זיהוי וטיפול - ההסתדרות הרפואית בישראל 2003.

איתור דיכאון

  • 220    Screening for depression: recommendations and Rationale - U.S. Preventive Task Force. Am Fam Phys 2002; 66(4): 647-650.
  • 221    Froom J. Sclager D. Stheker S, Jaff A. Detection of major depressive disorder in primary care patients. J Am Board Fam Pract 1993; 6: 5-11.

איתור סרטן העור

  • 222    Screening for skin cancer: Recommendation and rationale - U.S. Preventive services Task Force. Am Fam Phys 2002; 65(8): 1623-1626.
  • 223    Lamberg L. "Epidemic" of malignant Melanoma, True increase or better detection. JAMA 2002; 2879170; 2201

איתור מוקדם סרטן הריאה

  • 224   Mahadevial PJ, Fleisher LA, Frick KD Et al. Lung cancer screening with Helical Ccomputed Tomography in older adult smokers. JAMA 2003; 289(3): 313-322, 357-358.
  • 225    Swensen SJ. Screening for cancer with computed tomography. BMJ 2003; 326: 894-895.

איתור מוקדם של סרטן הערמונית

  • 226   Harris R, Lohr Kn Update of the U.S Preventive services Task Force on Screening for prostate cancer: recommendation and Rationale. Ann Intern Med 2002; 137: 917-929.
  • 227    Lu-Yao G, Albertsen PC, Stanfors JL et al. Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seatle area and Connecticut. BMJ 2002; 325: 740-244, 725.
  • 228   A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. Holmberg L, Bill-Axelson A, Helgesen F, Salo JO, Folmerz P, Haggman M, Andersson SO, Spangberg A, Busch C, Nordling S, Palmgren J, Adami HO, Johansson JE, Norlen BJ; Scandinavian Prostatic Cancer Group Study Number 4. N Engl J Med. 2002; 347: 781-9.
  • 229   Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Ryan A, Szczepanek CM, Crowley JJ, Coltman CA Jr. The Influence of Finasteride on the Development of Prostate Cancer. NEJM 2003; 349: 213-222.
  • 230    Frankel S, Smith GD, Donovan J, Neal D. Screening for prostate cancer. Lancet 2003; 361: 1122-1128.

איתור מוקדם של סרטן צוואר הרחם

  • 231   American cancer Society (ACS) Updates Guideline for the early detection of cervical neoplasia and cancer. Am Fam Physician 2003; 67(9): 2011-2016.
  • 232   Mohoney MC, Saslow D, Cohen CJ. ACS guideline for the early detection of cervical cancer. Am Fam Physician 2003; 67(8): 1677-1680.
  • 233   U.s Preventive Services Task Force. Screening for cervical cancer - recommendations and rationale. Am Fam Physician 2003; 67(8): 1759-1766.
  • 234   בורנשטיין י, אברמוביץ ח. חשיבות ביצוע סריקה המונית לגילוי מוקדם של סרטן צוואר הרחם במדינת ישראל. הרפואה 1992 כרך 122 חוב׳ יב׳, עמ׳ 180-176.

מניעת והפסקת עישון

  • 235   Jorenby D. Clinical efficacy of Buprpion in the management of smoking cessation. Drugs 2002; 62 suppl.2: 25-35.
  • 236    Rigotti NA. Treatment of tabacco use and dependence. N Eng J med 2002; 346(7): 506-512.
  • 237    www.nice.org.uk
  • 238    Guidance on the use of nicotine replacement therapy (NRT) and Bupropion for smoking cessation. Technology Appresial Guidenace - No 39 - Published by the National Institute for Clinical excellence (NICE) - March 2002.
  • 239    שטיינברג א, לוגר א, ממן ע, שטיינברג ש. השפעת העישון על מחלות אורתופדיות ותוצאות ניתוחים. הרפואה כרך 142 (ו): עמ׳ 445-442.
  • 240   Band PR, D Le N, Fang R, Deschamps M. Carcinogenic and endocrine disrupting effects of cigarette smoke and risk of breast cancer. The Lancet 2002; 360: 1044-1049,1033-1034.
  • 241   דו"ח שר הבריאות על העישון בישראל 2003-2002, סיוון התשס"ג, יוני 2003.
  • 242    Burns D, Garfinkel L, Samet J, eds. U.S. Department of Health and Human Services, Public Health Service. National Institutes of Health, National Cancer Institute. Changes in cigarette-related disease risks and their implication for prevention and control.Smoking and Tobacco Control Monograph No. 8, USDHHS National Cancer Institute, 1997; NIH Publication 974213.
  • 243   Zevin S, Benowitz NL. Drug interactions with tobacco smoking. An update. Clin Pharmacokinet 1999 36: 425-38.
  • 244   Burns DM. Nicotin Addiction. Harrison's Principles of Internal Medicine. 15th edition, pp 2574-2577.
  • 245   Fiore MC US public health service clinical practice guideline: treating tabacco use and dependence. Respir Care 2000; 45(10): 1200-1262.
  • 246    Anderson JE, Jorenby DE, Scott WJ, Fiore MC. Treating tabacco use and dependence: an evidence-based clinical practice guideline for tabacco cessation. Chest 2002; 121(3): 686-687.
  • 247    Liberman DA, Prindiville S, Weiss DG. et al Risk Factors for advanced colonic neoplasia and hyperplastic polyps in symptomatic individuals. JAMA 2003; 290(22): 2959-67.

חיסון כנגד אבעבועות רוח

  • 248   Skull SA, Wang EEL with the Canadian Task Force on Preventive Health Care Preventive health care, 2001 update: Use of varicella in healthy population 1999.
  • 249    Prevention of Varicella, Update recommendations of the advisory committee on immunization practices. MMWR 1999; 48(6). U/S Department of Health and Human services.
  • 250    Varicella Vaccine update - Committee of infectious disease- American Academy of Pediatrics/
  • 251    Maharshak N, Somekh E. Hospitalization for varicella in center Israel. Accta Pediatr 1999; 88: 1-5.
  • 252    Tan AYS, Connett CJ, Connett GJ et al. Use of reformulated Oka strain varicella vaccine in healthy childern. Eur J Pediatrics 1996; 155: 706-11.
  • 253   Oxman MN. Immunization to reduce the frequency and sevirity of herpez zoster and its complications. Neurol 1995; 45(Suppl 8): S41-6.
  • 254   Gershon A, Silverstein S. Live attenuated varicella vaccine for prevention of Herpes zoster. Biologicals 1997; 25: 227-30.
  • 255    White CJ. Varicella Zoster virus vaccine. Clin Infec Dis 1997; 24: 753-63.

איתור מוקדם של סרטן המעי

  • 256    ח. סטרול, ר. אליקים, ז. הלפרין, נ. ארבר. מניעה וגילוי מוקדם של סרטן הכרכשת בכלל האוכלוסיה - יום עיון וסיכום עמדת האיגוד לגסטרואנטרולוגיה. הרפואה, 2003 כרך 142(3) עמ׳ 226-223.
  • 257   Walsh JME, Terdiman JP. Colorectal cancer screening. JAMA 2003; 289: 1288-1296.
  • 258    Sonnenberg A, Dele F. Cost effectiveness of single colonoscopy in screening for colorectal cancer. Arch Intern Med 2002; 162: 163-168.
  • 259    Preventive Health Care, 2001 update: Colorectal Cancer Screening. Prapered by McLeod R with the Canadian task force on Preventive health care. www.ctfphc.org/Tables/C010r-ectal_Ca_tab.htm.
  • 260    www.cmaj.ca/cgi/content/full
  • 261    Boyle P. Faecal occult blood testing (FOBT) as screening for colorectal cancer: The current controversy. Ann One 2002; 13(1): 16-18.
  • 262    Detsky AS. Screening for colon cancer - can we efford colonoscopy? N Eng J Med 2001; 345(8): 607-608.
  • 263    Imperiale TF, Wagner DR, Lin Ch Y et al. Results of screening colonoscopy among persons 40 to 49 years of age. N Eng J Med 2002; 346: 1781-1785.
  • 264   Pickhard PJ, Choi R, Hwong I et al. Computed tomographic virtual colonoscopy to screen for colorectal neoplasia in asymptomatic adults. N Eng J M 2003; 349: 2191-2200.

פעילות גופנית, השמנת יתר, יתר לחץ דם, היפרכולסטרולמיה ומניעת מחלות לב

  • 265   Kraus WE et al Effects of the amount and intensity of exercise on plasma lipoproteins. N Eng J Med 2002; 347: 1483-1492.
  • 266   Tall AR. Exercise to reduce cardiovascular risk - How much is enough? N Eng J Med 2002; 347: 1522-1524.
  • 267    Fontaine KR, Redden DT, Wang Ch. Years of life lost due to obesity. JAMA 2003; 289: 187-193.
  • 268    Calle EE, Rodriguez C, Walker-Thurmond K, Thun M. Overweight, obesity and mortality from cancer in a prospectively studies cohort of U.S. adults. N Eng J Med 2003; 348: 1625-1638.
  • 269   פולגמן י וחב׳ הנחיות קליניות בנושא מניעה וטיפול בהשמנת יתר. בהוצאת ההסתדרות .270 הרפואית בישראל 2003.
  • 270   Eatabrooks PA, Glasgow RE, Dzewaltowski DA. Physical activity promotion through primary care. JAMA 2003; 289: 2913-2916.
  • 271   Key TJ, Allen NE, Spencer EA, Travis RC. The effect of diet on risk of cancer. Lancet 2003; 361(9353): 257-258.
  • 272   Chobanian AV, Bakris GL, Black HR et al -and the National High Blood Pressure Education Program Coordinating Committee. The seventh report of the joint national committee on prevention, detection, evaluation and treatment of high blood pressure. JAMA 2003; 289: 2560-2572.
  • 273   Elley CR, Kerse N, Arroll B, Robinson E. Effectiveness of counseling patients on physical activity in general practice: cluster randomized controlled trial. BMJ 2003; 326: 793-796.
  • 275   Hermansen K, Dinesen B, Hoie LH et al. Effects of soy and other natural products on LDL: HDL ratio and other lipid parameters: a literature review. Adv Ther 2003; 20(1): 50-78.
  • 276   LaRosa JC. Understanding the risk of hypercholesterolemia. Cin Cardiol 2003; 26(1 supple 1): I 3-6.
  • 277   Shepherd J, Gaw A. West of Scotland Coronary Prevention Study Group. The Anatomy of a clinical trial. The West of Scotland Coronary Prevention Study. Med Princ Pract 2002; 11 Suppl 2: 17-30.
  • 278    2003 European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. Guidelines Committee. J of Hypertension 2003; 21: 1011-1053.
  • 279   2003 European Society of Hypertension – European Society of Cardiology guidelines for the management of arterial hypertension.. J Hypertens 2003; 21: 1011-1053.
  • 280   Chobanian AV, Bakris GL, Black HR et al, The Seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. JAMA 2003; 289(19): 2560-2570.
  • 281   Downs JR., Clearfield M., Wies S., et al. 1998 Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA. 279: 1615-622.
  • 282   Lewis SJ., Sacks FM., Mitchell JS., et al. 1998 Effect of pavastain on cardiovascular events in women after myocardial infarction: the Cholesterol and Recurrent Events (CARE) Trial. J Am Colleague Cardiol. 32: 140-146
  • 283   הנחיות והמלצות בנושא טיפול ומניעה של מחלת לב כלילית וטרשת עורקים - בעריכת חרץ ד. ורובנשטיין א. - ההסתדרות הרפואית בישראל והאגף לאבטחת איכות 1999.
  • 284   דף עמדה מטעם המועצה הלאומית למניעת מחלות לב בנושא מניעה ראשונית של מחלת לב כלילית וכלי דם באוכלוסיה הבוגרת - יו"ר - פרופ׳ צבעוני. 2003.
  • 285   Prevention and control of non-communicable diseases. In: Fifty-fifth World Health Assembly, Geneva, 13-18 May 2002. Vol 1. Geneva, World Health Organization, 2002: 28-30.
  • 286    Pushka P. Changes in premature deaths in Finland: successful long-term prevention of cardiovascular diseases. Bulletin of the World Health Organization, 1998; 76: 416-25.

תזונה נכונה

  • 287   World Cancer Research Fund. Food, nutrition and the prevention of cancer: a global perspetive. Washington DC, American Institute for Cancer Research, 1997.
  • 288    Stubbs J, Ferres S, Horgan G. Energy density of foods: effects on energy intake. Critical Reviews in Food Science and Nutrition, 2000; 40: 481-515.
  • 289    Rolls BJ, Bells EA. Dietary approaches to treatment of obesity. Medical Clinics of North America., 2000; 40: 401-18.
  • 290    Depres JP. Treatment of obesity: need to focus on high-risk abdominally obese patients. British Medical Journal 2002; 322: 716-20.
  • 291    Tuomilehto J et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med, 2002; 346: 393-403.
  • 292    Mann J. Dietary fibre and diabetes revisited. Eur J Clin Nutr 2000; 55: 919-21.
  • 293    Oomen CM et al. Association between trans fatty acid intake and 10-year risk of coronary heart disease in the Zutphen Elderly Study: a prospective population-based study. Lancet 2001; 357: 746-51.
  • 294    Sacks FM et al. Effects on blood pressure of reduced dietary sodium and the Diertary Approaches to Stop Hypertension (DASH) diet. N Engl J Med 2001; 344: 3-10.
  • 295   Burr ML et al. Effectrs of changes in fat, fish and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet 1989; 2: 757-61.
  • 296    Smith-Warner SA et al. Intake of fruits and vegetables and risk of breast cancer: a pooled analysis of cohort studies. J Am Med Assoc 2001; 285: 769-76.
  • 297    Nitzan Kaluski D, Ophir E, Kachal J, Shamir R, Eidelman A, Amitai Y, Boujanover Y, Baram N, Hisdai N, Haviv A, Branski D. Nutritional guidelines for infants and toddlers. Ministry of Health, Israel 2001.
  • 298    Kaluski DN, Leventhal A., Averbuch Y, Rishpon S, Cohen-Dar M, Habib S, Bellmaker I, Rubin L, Rachmiel S, Amitai Y and Palti H. Five decades of trends in iron deficiency anemia in Israeli infants: implications for food fortification policy. Eur J Clin Nutr 2001; 55: 82-7.
  • 299    Kaluski DN Chinich A, Leventhal A, Ifrah A, Cohen-Mannheim I, Merom D, Green MS. Overweight, stature, and socioeconomic status among women-cause or effect: Israel National Women's Health Interview Survey, 1998. J Gend Specif med. 2001; 4: 18-24.
  • 300    Steptoe A, Perkins-Parras L. Behavioral counseling to increase consumption of fruit and vegetables in low income adults randomized trial. BMJ 2003; 326: 855-861.
  • 301    Key TJ, Allen NE, Spencer EA, Travis RC. The effect of diet on risk of cancer. Lancet 2002; 360(9336): 861-868.

רפואת מטיילים וטיסה

  • 303   Fundamentals of Aerospace Medicine, Dehart RL and Davis JR editors, Lippincott Williams & Wilkins, Philadelphia, PA 2002 (see Chapter 11, Health Maintenance and Promotion, co-authored by the author of this chapter).
  • 304   Clinical Aviation Medicine, 3rd ed 2000, Rayman RB, Castle Connoly Graduate Medical Publishing, LLC New York, NY.
  • 305   Aerospace Medical Asssociation Medical Guidelines Task Force. Medical guidelines for airline travel, 2nd ed. Aviation Space & Environmental Medicine 2003; 74(S): 1-19.
  • 306   Zuckerman JN. Clinical Review-Recent developments: Travel Medicine. BMJ 2002; 325: 260-264.
  • 307   Herxheimer A, Waterhouse J.The prevention and treatment of jet lag. BMJ 2003; 326: 296-297.
  • 308    Bagshaw M. et al. Travellers Thrombosis: A Review of Deep Vein Thrombosis Associated with Travel. Aviat Space Envir Med 2001; 72: 848-51.
  • 309    Wenzel RP. Airline Travel and Infection. N Engl J Med; 334: 981-2.
  • 310   Samel A, Wegmann HM. Bright light: A countermeasure for jet lag? Chronobiol Int 1997; 14: 173-183.

מניעת מחלות לב וסרטן באמצעות תרופות - אספירין, טמוקסיפן, ולוקסיפן

  • 312   Hyden M, Pignone M, Philips Ch, Mulrow C. Aspirin for the primary prevention of cardiovascular events. Ann Int Med 2002; 136(2): 161-172.
  • 313   Herbert PR, Hennekens CH. An overview of the 4 randomized trials of aspirin therapy in the primary prevention of vascular disease. Arch Intern Med 2000; 160: 3123-3127.
  • 314   Sanmuganathan PS, Ghahramani P, Jackson PR, et al. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomized trials. Heart 2001; 85: 265-271.
  • 315   Baron JA, Cole BF, Sandler RS et al. A randomized trial of Aspirin to prevent colorectal adenomas. N Eng J Med 2003; 348: 891-899.
  • 316   Imperiale TF. Aspirin and the prevention of colorectal cancer. N Eng J Med 2003; 348: 879-880.
  • 317   Barrett-Connor E, Grady D, Sashegyi A et al. raloxifene and cardiovascular events in osteoporotic postmenopausal women. JAMA 2002; 287(7): 847-857.
  • 318   Cummings SR, Eckert S, Krueger KA et al. The effect of Raloxifene on risk of breast cancer in postmenopausal women. JAMA 1999; 281(23): 2189-2197,2243
  • 319   Levine M, Moutquin JM, Walton R, Feightner J - Canadian Task Force. Chemoprevention of breast Cancer www.ctfphc.org/Tables_printable/Chemoprev_tab_p.htm
  • 320   Cauley JA , Norton L, Lippman ME et al For the MORE Investigators. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4 year results from the MORE trial. BREAST Cancer Research and treatment 2001; 65: 125-134.
  • 321   Hennekens CH. Update on aspirin in the treatment and prevention of cardiovascular disease. Am J Manag Care 2002; 8(22 suppl): s691-700.
  • 322   Mehta P. Aspirin in the prophylaxis of coronary artery disease. Curr Opin Cardiol 2002; 17(5): 552-558.
  • 323   Sexton RC jr. Aspirin in cardiovascular disease. Tenn Med 2001; 94(6): 208-210.
  • 324   Virtamo J, Pietinen P, Huttunen JK, Korhonen P et al;ATBC Study Group. Incidence of cancer and mortality following alpha-tocopherol and beta-carotene supplementation: a postintervention follow-up. JAMA 2003; 290: 476-485.

אוסטיאופורוזיס

  • 325    אוסטיאופורוזיס לאחר גיל המעבר - איבחון, מניעה וטיפול. דו"ח הועדה מטעם העמותה הישראלית לאוסטיאופורוזיס ומחלת עצם. בעריכת פולדש יוסף ובהוצאת ההסתדרות הרפואית בישראל 2002.
  • 326   Sarkar S, Mitlak BH, Wong M et al. Relationships between bone mineral density and incident of vertebral fracture risk with raloxifene therapy. J Bone Miner Res 2002; 17:1-10.
  • 327   Delmas PD. Treatment of postmenopausal osteoporosis. The Lancet 2002; 359: 2018-2026.
  • 328   Riggs BL, Hartmann LC. Selective Estrogen Receptor Modulators _ Mechanisms of Action and Application to clinical practice. N Engl J Med 2003; 348: 618-629.
  • 329   Santoro N. F. ,Col N.F., Eckman M.H., Wong J.B., Pauker S.G., Cauley J.A., Zmuda J., Crawford S., Johannes C.B., Rossouw J.E., Merz C.N.B. Hormon Replacement Therapy -Where are we going? JCEM 1999; 84; 6: 1798-1799.
  • 330   Battett-Connor E., Stuenkel C. Hormones and heart disease in women: Heart and estorgen/progestin replacement study in perspective. JCEM 1999; 84; 6: 1848-9.
  • 331   Miller P.D., Zapalowski C, Kulak C.A.M., Bilezikian J.P. Bone densitometry: The best way to detect Osteoporosis and monitor therapy. JCEM 1999; 84; 6: 1867-8.
  • 332   Nelson HD, Harris E., Cauley J., et al. 1998 Osteoporosis and fracture are common in older postmenopausal women using estrogen. Bone. 23: SI52.
  • 333   Kleerekoper M. Lessons from the skeleton: was the Women's Health Initiative (WHI) a primary prevention trial? Osteoporos Int. 2002 Sep; 13(9): 685-7.
  • 334   Delmas PD, Ensrud KE, Adachi JD, Harper KD, Sarkar S, Gennari C, Reginster JY, Pols HA, Recker RR, Harris ST, Wu W, Genant HK, Black DM, Eastell R; Mulitple Outcomes of Raloxifene Evaluation Investigators. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab. 2002 Aug; 87(8): 3609-17.
  • 335   Siris E, Adachi JD, Lu Y, Fuerst T, Crans GG, Wong M, Harper KD, Genant HK. Effects of raloxifene on fracture severity in postmenopausal women with osteoporosis: results from the MORE study. Multiple Outcomes of Raloxifene Evaluation. Osteoporos Int. 2002 Nov; 13(11): 907-13.
  • 336   Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang 0, Mitlak BH. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001 10; 344(19): 1434-41.
  • 337   Osteoporosis Prevention, Diagnosis and Therapy. NIH Consensus Statement Online. 2000; 17(1): 1-36. Available at: http//odp.od.nih.gov/consensus/cons/lll/lll_statement.htm. Accessed February 27, 2002.
  • 338   Screening for osteoporosis in postmenopausal women - U.S Preventive Services Task Forse. Third Edition: Periodic Updates Sep 2002 P 211-217.

ויטמינים למניעת מחלות

  • 339   Lebenthal E, Shapira N. Nutrition in the female life cycle. Published by ISAS International Seminar Ltd. Jerusalem & Danone Institute 2001.
  • 340    Willett WC, Stampfer MJ. What vitamins should I be taking, Doctor? NEJM 2001; 345: 1819-1824.
  • 341    Fletcher RH, Fairfield KM. Vitamins for chronic disease prevention. JAMA 2002; 287: 3127-3129.
  • 342    Morris CD, Carson S. With the U.S. Preventive Services Task Force. Routine vitamin supplementation to prevent cancer and cardiovascular disease: Recommendations and rationale. Ann Intern. Med 2003; 139: 51-70.

טיפול הורמונלי בגיל המעבר

  • 343    פינס ע. טיפול הורמונלי חלופי בגיל חדילת אורח למניעת מחלות לב - החלום שנגוז? הרפואה כרך 142 (ג) עמ׳ 165-163.
  • 344   Mendelsohn ME & Karas RH, The protective effects of estrogen on the cardiovascular system. N Eng J Med 1999; 340: 1801-1811.
  • 345   Herrington DM, Reboussin KB, Brosnihan KB et al. effects of estrogen replacement on the progression of coronary artery atherosclerosis. N Eng J Med 2000; 343: 522-529.
  • 346   Poulter N. Oestrogen and protection against cardiovascular disease: potential versus reality.Epidemiology 2001; 8(6): 383-390.
  • 347   Writing group for the Women's Health Initiative Investigators. Risks and benefits from the women's Health Initiative in healthy postmenopausal women. JAMA 2002; 288: 321-333.
  • 348   Stevenson JC & Whitehead IM. Hormone replacement therapy. Findings of Women's Health Initiative trial need not alarm users. BMJ, 2002; 325: 113-114.
  • 349   Chlebowski RT, hendrix SL, Langer RD et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women- The women's health initiative randomized trial. JAMA 2003; 289: 3243-3253.
  • 350   Li Ch.I, Malone KE, Porter PL et al. Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA 2003; 289: 3254-3263.
  • 351   Gann PH & Morrow M. Combined hormone therapy and breast cancer - A single edged sword. JAMA 2003; 289: 3304-3308.
  • 352   מצב הבריאות בישראל, משרד הבריאות - המרכז הלאומי לבקרת מחלות 1997, פרסום 202 עמ׳ 65.
  • 353   Brewer D. What nonhormonal therapies are effective for postmenopausal vasomotor symptoms? J Fam Pract 2003; 52(4): 324-325.
  • 354   Hays J, Ockene JK, Brunner RL et al. Effects of estrogen plus progestin on health related quality of life. N Engl J Med 2003; 348(19): 1839-54
  • 355   Rymer J, Wilson R, Ballard K. Making decisions about hormone replacement therapy. BMJ 2003; 326: 322-326.
  • 356   Petitti DB, Hormone replacement therapy for prevention. JAMA 2002; 288(1): 99-101.
  • 357   Fletcher SW, Colditz GA. Failure of estrogen plus progestin therapy for prevention. JAMA 2002; 288: 366-368.
  • 358   Stampfer MJ, Colditz GA, Willett WC, Manson JE, Rosner B, Speizer FE, Hennekens CH. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study. N Engl J Med 1991 Sep 12; 325(11): 756-62
  • 359   Grodstein F, Stampfer MJ, Manson JE, Colditz GA, Willett WC, Rosner B, Speizer FE, Hennekens CH. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996 Aug 15; 335(7): 453-61
  • 360   Hulley S, et al. Randomized trail of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. HERS JAMA 1998; 280: 605-13.
  • 361   Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton LA, Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 2000; 283: 485-491.
  • 362   Ross RK, Paganini-Hill A, Wan P, Pike M. Effect of hormone replacement therapy on breast cancer: estrogen versus estrogen plus progestin. J Natl Cancer Inst.2000; 92: 328-332
  • 363   Chen CL, Weiss NS, Newcomb P, Barlow W, White E. Hormone replacement therapy in relation to breast cancer. JAMA 2002; 287: 734-741.
  • 364   Merom D, Ifrah A, et al. Factors predicting current use of hormone replacement therapy among menopausal Jewish women in Israel. IMAJ 2002; 4: 671-676.
  • 365   Nelson HD, Humphrey LL, Nygren P et al. Postmenopausal hormone replacement therapy. JAMA 2002; 288: 872-81
  • 366   Sillero-Arenas M et al. Menopausal hormone replacement therapy and breast cancer: a meta-analysis. Obstet Gynecol 1992; 79: 286-294.
  • 367   Colditz GA et al. Hormone replacement therapy and risk of breast cancer: results from epidemiologic studies. Am J Obstet Gynecal 1993; 168: 1473-80
  • 368   Hulley S, Furberg C, Barrett-Connor E, Cauley J, Grady D, Haskell W, Knopp R, Lowery M, Satterfield S, Schrott H, Vittinghoff E, Hunninghake D; HERS Research Group. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA. 2002; 288: 58-66.
  • 369   Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, Hsia J, Hulley S, Herd A, Khan S, Newby LK, Waters D, Vittinghoff E, Wenger N; HERS Research Group. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA. 2002; 288: 49-57
  • 370   Wassertheil-Smoller S, Hendrix SL, Limacher M, Heiss G, Kooperberg C, Baird A, Kotchen T, Curb JD, Black H, Rossouw JE, Aragaki A, Safford M, Stein E, Laowattana S, Mysiw WJ; WHI Investigators. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA. 2003; 289: 2673-84.
  • 371   Rapp SR, Espeland MA, Shumaker SA, Henderson VW, Brunner RL, Manson JE, Gass ML, Stefanick ML, Lane DS, Hays J, Johnson KC, Coker LH, Dailey M, Bowen D; WHIMS Investigators. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003; 289: 2663-72.
  • 372   Shumaker SA, Legault C, Thai L, Wallace RB, Ockene JK, Hendrix SL, Jones BN 3rd, Assaf AR, Jackson RD, Kotchen JM, Wassertheil-Smoller S, Wactawski-Wende J; WHIMS Investigators. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003; 289: 2651-62
  • 373   Million women study collaboration. Breast cancer and hormone replacement therapy in the Million Women study. Lancet 2003; 362; 419-427.
  • 374   Blake JM, Collins JA, Reid RL, Fedorkow DM, Lalonde AB, Christilaw J, Fortier M, Fortin C, Jolly EE, Lemay A, O'Grady T, Smith TE, Cooper J, Maxted JM, O'Grady K, Turek MA; SOGC (Society of Obstetricians and Gynaecologists of Canada). The SOGC statement on the WHI report on estrogen and progestin use in postmenopausal women. J Obstet Gynaecol Can. 2002 Oct; 24(10): 783-90, 793-802.

איתור מוקדם של סרטן השד

  • 375   Miller AB, To T, Baines C, Wall C. Canadian National Breast Screening Study-2: 13 year results of a randomized trial in women aged 50-59 years. JNCI 2000; 92: 1490-1499.
  • 376    Ringash J. Canadian task force on preventive Health Care. Screening mammography among women aged 4049 years of age at average risk of breast cancer. CMAJ 2001; 164: 469476.
  • 377    Gotzsche PC, Olsen 0. Is screening for breast cancer with mammography justifiable? Lancet 2000; 355: 129-134.
  • 378    Olsen 0, Gotzsche PC. Cochrane review on screening for breast cancer with mammography. Lancet 2001; 358: 1340-1342.
  • 379   EBCG editors, Cochrane Collaboration - Screening mammography: setting the record straight. Lancet 2002; 359: 439-440.
  • 380   Horton R. Screening mammography - an overview revisited. Lancet 2001; 358: 1284-1285.
  • 381   Miettinen OS, Henschke CI, Pasmantier MW et al. Mammographic screening: no reliable supporting evidence? Lancet 2002; 359: 404-405.
  • 382   Tabar L, Smith RA, Duffy SW. Update on effects of screening mammography. Lancet 2002; 360: 337; 339-340.
  • 383   Tabar L, Yen MF, Vitak B et al. Mammography service screening and mortality in breast cancer patients: 20 year follow up before and after introduction of screening. Lancet 2003; 361(9367): 1405-1410.
  • 384   Humphrey LL, Helfand M, Chan BK, Woolf SH. Breast cancer screening: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002; 347-360, 363-365, 147.
  • 385   U.S. Preventive Services Task Force. Screening for breast cancer: recommendation and rationale. Am Fam Physician 2002; 65 (12): 2537-2544.
  • 386    Chemoprevention of Breast Cancer. Canadian Task Force recommendations www.ctfphc.org/references/chemoprev_bib.htm
  • 387   Rebbeck TR, Lynch HT, Neuhausen SL et al; Prevention and Observation of Surgical End Points Study Group. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002; 346: 1616-1622.
  • 388    Meijers-Heijboer H, van Geel B, van Putten WL, Henzen-Logmans SC, Seynaeve C, Menke-Pluymers MB, Bartels CC, Verhoog LC, van den Ouweland AM, Niermeijer MF, Brekelmans CT, Klijn JG. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2001 Jul 19;345(3):159-64.
  • 389   Thomas DB, Gao DL, Ray RM, Wang WW, Allison CJ, Chen FL, Porter P, Hu YW, Zhao GL, Pan LD, Li W, Wu C, Coriaty Z, Evans I, Lin MG, Stalsberg H, Self SG. Randomized trial of breast self-examination in Shanghai: final results. J Natl Cancer Inst. 2002; 94: 1445-57.
  • 390   Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group. Lancet 1998; 351: 1451-67.
  • 391   Humphrey LL, Helfand M, Chan BK, Woolf SH. Breast cancer screening: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2002; 137: 347-60.
  • 392   Gotzsche PC, Olsen 0. Is screening for breast cancer with mammography justifiable? Lancet. 2000; 355: 129-34.
  • 393   John EM, Kelsey JL. Radiation and other environmental exposures and breast cancer. Epidemiol Rev 1993; 15: 157.
  • 394    אלוייס ת.מ, ניסן א, שפירא ר.מ. סקלייר־לוי מ, פרוינד ה, פרץ ת. ממוגרפיה סוקרת לאיבחון מוקדם של סרטן השד: העובדות, המחלוקות והיישום בישראל. הרפואה 2003, כרד 142 (ד) עמ׳ 286-281.

מניעה במבוגרים

  • 395   Preventive services for adults, Institute for clinical systems improvement (ICSI), Bloomington, Minnesota, March 2000.
  • 396    American college of Sports Medicine (ACSM) Position Stand - Exercise and physical activity for older adults. Medicine and Science in sports & exercise. Volume 29, no. 6 1998.
  • 397    Tinetti ME. Preventing falls in elderly persons. N Engl J Med 2003; 348: 42-49.
  • 398   Feskanich D et al. Walking and leisure time activity and risk of hip fructure in postmenopausal women JAMA 2002; 288: 2300-2306.
  • 399    Heflin MT, Cohen HJ. Duke University. Cancer Screening in the Elderly/ www.hosp-pract.com/issues/2001/03/eldhef.htm
  • 400    גלינסקי וחב׳. מבחנים לאיתור זקנים בעלי סיכון גבוה לנפילות בקהילה ופרוטוקולים נלווים - מסקנות מפרוייקט למניעת נפילות קשישים בבאר שבע. הרפואה 2000 כרד 138(ג) עמ׳ 194-189.

מניעת מחלות כבד

  • 401   Clinical research workshop, The American Association for the study of Liver Diseases, Screening in Liver Disease.
  • 402    Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002; 36: S35-S46.
  • 403    El-Serag HB. Hepatocellular carcinoma and hepatitis C in the united states. Hepatology 2002; 36: S74-S83.
  • 404    Center for disease control and prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR 1998; 47(N0 RR-19); 1-39.
  • 405    Alter MJ. Epidemiology and prevention of hepatitis B. Semin Liv Dis 2003; 23: 39-46.
  • 406   Margolis HJ, Alter MJ, Hadler SC. Hepatitis B: Evolving epidemiology and implications for control. Sem Liv Dis 1991; 11: 84-92.
  • 407    Fattovich G. Natural history and prognosis of hepatitis B. Sem Liv Dis 2003; 23: 47-58.
  • 408   Marchesini G, Bugianesi E, Forlani G, Rizzetto m et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37: 917-923.
  • 409    McLaren C, Barton J, Adams P, Harris E, Acton R, Press N et al. Hemochromatosis and iron overload screening (HEIRS) Study design for an evaluation of 100,000 primary care-based adults. Am J Med Sci 2003; 325: 53-62.

הסינדרום המטבולי

  • 410   Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), Executive Summary NIH Publication No. 01-3670, May 2001.
  • 411    Ian Janssen; Peter T. Katzmarzyk; Robert Ross. Body Mass Index, Waist Circumference, and Health Risk: Evidence in Support of Current National Institutes of Health Guidelines. Arch Intern Med. 2002; 162: 2074-2079.
  • 412    Reaven GM. Banting Lecture. Role of Insulin resistance in human disease. Diabetes 1988; 37: 1595-607.
  • 413    Reaven GM. Role of insulin resistance in human disease (syndrome x): an expanded definition. Annu Rev Med 1993; 44: 121
  • 414   Reaven et al. Hypertension and associated metabolic abnormalities - the role of insulin resistance and the sympathoadrenal system. N Eng J Med 1996; 334: 374
  • 415    Brunner EJ, Hemingway H, Walker BR, Page M, Clarke P, Juneja M, Shipley MJ, Kumari M, Andrew R, Seckl JR, Papadopoulos A, Checkley S, Rumley A, Lowe GD, Stansfeld SA, Marmot MG. Adrenocortical, autonomic, and inflammatory causes of the metabolic syndrome: nested case-control study. Circulation 2002 Nov 19; 106(21): 2659-65.
  • 416    Ridker PM et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Eng J Med. 2002; 347: 1557.
  • 417    Rader DJ. Inflammatory markers of coronary risk. NEJM 2000; 343: 1179.
  • 418    Tall AR. Exercise to Reduce Cardiovascular Risk-How Much Is Enough? N Eng J Med 2002; 347: 1522
  • 419    Ginsberg HN. Insulin resistance and cardiovascular disease. J Clin Invest 2000; 106: 453.
  • 420   Tuomiletho J et al. The Finnish Diabetes Prevention Study Group. Prevention of type 2 Diabetes mellitus by changes UN lifestyle among subjects with impaired glucose tolerance. N Eng J Med 2001; 344: 1344.

יישום הנחיות רפואיות

  • 421   Solberg LI. Guideline Implementation: What the Literature Doesnt Tell Us. J Qual Improv 2000; 26: 525-36.
  • 422    Weingarten S. Using Practice Guideline Compendiums To Provide Better Preventive Care. Ann Int Med 1999; 454-8.
  • 423    Solberg LI, Kottke TE, Brekke ML. Will Primary care Clinics Organize Themselves to Improve the Delivery of Preventive Services? A Randomized Controlled Trial. Prev Med 1998; 27: 623-31.
  • 424    Gottlieb NH et al. The impact of Put Prevention into Practice on selected clinical preventive services in five Texas sites. Am J Prev Med 2001; 21: 35-40.
  • 425    Goodwin MA et al. A Clinical Trial of Tailored Office Systems for Preventive Service Delivery. The Study to Enhance Prevention by Understanding Practice (STEP-UP). Am J Prev Med 2001; 21: 20-28.
  • 426    Cornuz J et al. Physicians' attitudes towards prevention: importance of intervention-specific barriers and physicians' health habits. Fam Pract 2000; 17: 535-40.
  • 427    Hash RB, Munna RK, Vogel RL, Bason JJ. Does Physician Weight Affect Perception of Health Advice? Prev Med 2003; 36: 4144.
  • 428   Pal B. The doctor will text you now: is there a role for the mobile telephone in health care? BMJ 2003; 326; 607.